SC Bricomat SA (BVB:COBL)

Checkpoint Therapeutics Income Statement

Financials in millions RON. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2019
Period Ending	Dec 31, 2024	Jan 1, 2024	Dec 31, 2022	Jan 1, 2022	Dec 31, 2019
Revenue	0.59	0.57	0.51	0.96	1.35
Revenue Growth (YoY)	3.21%	12.21%	-46.86%	-29.19%	30.84%
Cost of Revenue	0.32	0.22	0.28	0.26	0.66
Gross Profit	0.27	0.35	0.23	0.7	0.69
Selling, General & Admin	0.37	0.34	0.32	0.48	0.15
Other Operating Expenses	0.15	0.67	0.16	-0.23	0.4
Operating Expenses	0.57	1.06	0.53	0.29	0.61
Operating Income	-0.3	-0.71	-0.31	0.41	0.08
Interest Expense	-	-	-0.64	-	-
Interest & Investment Income	-	0	0.71	-	-
Pretax Income	-0.3	-0.71	-0.24	0.41	0.08
Net Income	-0.3	-0.71	-0.24	0.41	0.08
Net Income to Common	-0.3	-0.71	-0.24	0.41	0.08
Net Income Growth	-	-	-	379.38%	-
Shares Outstanding (Basic)	1	-	1	-	1
Shares Outstanding (Diluted)	1	-	1	-	1
EPS (Basic)	-0.29	-	-0.24	-	0.08
EPS (Diluted)	-0.29	-	-0.24	-	0.08
Gross Margin	45.80%	61.73%	44.34%	73.15%	51.14%
Operating Margin	-50.73%	-123.69%	-60.38%	42.35%	6.25%
Profit Margin	-50.73%	-123.67%	-47.20%	42.35%	6.25%
EBITDA	-0.25	-0.66	-0.26	0.46	0.14
EBITDA Margin	-42.91%	-116.16%	-50.50%	47.69%	10.13%
D&A For EBITDA	0.05	0.04	0.05	0.05	0.05
EBIT	-0.3	-0.71	-0.31	0.41	0.08
EBIT Margin	-50.73%	-123.69%	-60.38%	42.35%	6.25%
Revenue as Reported	0.67	0.81	0.56	2.38	1.35

Updated Sep 30, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.